Evidence map›Paper›PMID 16528011›Full record

ArticleAmerican journal of respiratory cell and molecular biology2006

RANTES (CCL5) regulates airway responsiveness after repeated allergen challenge.

Toshiyuki Koya, Katsuyuki Takeda, Taku Kodama, Nobuaki Miyahara, Shigeki Matsubara, Annette Balhorn, Anthony Joetham, Azzedine Dakhama, Erwin W Gelfand

Open access · greenAbstract readComparative Study
In one paragraph

Article in American journal of respiratory cell and molecular biology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Chemokines and chemokine receptors in allergic rhinitis: from mediators to potential therapeutic targets.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2022
    Review
  7. Article
  8. Article
  9. iScience · 2021
    Article
  10. Article
  11. Article
  12. Biomarkers for Overweight in Adult-Onset Asthma.Journal of asthma and allergy · 2020
    Article
  13. Article
  14. Article
  15. Targeting CCL5 in inflammation.Expert opinion on therapeutic targets · 2013
    Review
  16. Article
  17. Article
  18. Article
  19. Differential effects of dendritic cell transfer on airway hyperresponsiveness and inflammation.American journal of respiratory cell and molecular biology · 2009
    Article
  20. Chemokine complexity: the case for CCL5.American journal of respiratory cell and molecular biology · 2006
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Toshiyuki KoyaDepartment of Pediatrics, Division of Cell Biology, National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA.
Katsuyuki Takeda
Taku Kodama
Nobuaki Miyahara
Shigeki Matsubara
Annette Balhorn
Anthony Joetham
Azzedine Dakhama
Erwin W Gelfand
National Jewish Health · US

Funding

Signaling Memory in Chronic AsthmaP01HL036577 · NHLBI · NATIONAL JEWISH HEALTH · PI GELFAND, ERWIN WILLIAM · 1986 to 2011
$18.7M
RSV ENHANCES SENSITIZATION AND AIRWAY RESPONSIVENESSR01HL061005 · NHLBI · NATIONAL JEWISH HEALTH · PI GELFAND, ERWIN WILLIAM · 1999 to 2007
$2.2M
NHLBI NIH HHS HL-36577NHLBI NIH HHS HL-61005NHLBI NIH HHS P01 HL036577
6 · The paper itself

Abstract

RANTES (CC chemokine ligand 5) contributes to airway inflammation through accumulation of eosinophils, but the exact role of RANTES (CCL5) is not defined. C57BL/6 mice, sensitized by injection of ovalbumin (OVA) on Days 1 and 14, were challenged with OVA on Days 28, 29, and 30 (3 challenges, short-term-challenge model) or on Days 28, 29, 30, 36, 40, 44, and 48 (7 challenges, repeated-challenge model) and evaluated 48 h later. Anti-mouse RANTES was given intravenously, and recombinant mouse RANTES or PBS was given intratracheally. These reagents were given on Days 28, 29, and 30 in the short-term-challenge study and on Days 44 and 48 in the repeated-challenge study. After short-term challenge, there were no effects after administration of anti-RANTES or RANTES. In the repeated-challenge study, although control mice showed a decrease in airway hyperresponsiveness, administration of anti-RANTES sustained and enhanced airway hyperresponsiveness and increased goblet cell numbers. In contrast, administration of RANTES normalized airway function but reduced goblet cell numbers. IL-12 and IFN-gamma levels in BAL decreased in the anti-RANTES group and increased in the RANTES group. IFN-gamma-producing CD4 T cells in lung, and IFN-gamma production from lung T cells in response to OVA in the anti-RANTES group, were significantly decreased but were increased in the RANTES group. Anti-IFN-gamma, administered with RANTES, decreased the effects of RANTES on AHR after repeated challenge. These data indicate that RANTES plays a role in the regulation of airway function after repeated allergen challenge, in part through modulation of levels of IFN-gamma and IL-12.

Indexed as

AllergensAnimalsBronchoalveolar Lavage FluidChemokine CCL5FemaleInterferon-gammaInterleukin-12MiceMice, Inbred C57BLOvalbuminRecombinant ProteinsRespiratory HypersensitivityAllergensChemokine CCL5Interferon-gammaInterleukin-12OvalbuminRecombinant Proteins

Identifiers

PMID16528011
PMCPMC2643254
OpenAlexW2110645241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.